Myocarditis, Pericarditis

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

RNA Therapeutic
1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Moderna
ModernaCAMBRIDGE, MA
1 program
mRNA-1273N/ARNA Therapeutic1 trial
Active Trials
NCT06113692Completed1,169Est. Jun 2025

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
ModernamRNA-1273

Clinical Trials (1)

Total enrollment: 1,169 patients across 1 trials

A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 Vaccine

Start: Mar 2023Est. completion: Jun 20251,169 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space